Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing

ABSTRACT: TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing

PROVIDER: PRJNA415199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6196820.fastq.gz	Fastqsanger.gz
	SRR6196830.fastq.gz	Fastqsanger.gz
	SRR6196850.fastq.gz	Fastqsanger.gz
	SRR6196870.fastq.gz	Fastqsanger.gz
	SRR6196890.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 3436

Similar Datasets

TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing [validation in cell lines Figure 2 and Figure S3]

Project description:TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing [validation in cell lines Figure 2 and Figure S3]

| PRJNA415204 | ENA

TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing [validation in cell lines; Figure 2 and Figure S3]

Project description:We developed TARGET-seq, a single-cell genotyping and RNA-seq method, which allows accurate detection of multiple mutations within single-cells from genomic and coding DNA in parallel with whole transcriptome analysis, providing a powerful tool to link transcriptional and genetic tumor heterogeneity. Single cell whole transcriptome analysis of JURKAT, SET2 and HSPCs using SMART-seq+, mRNA targeting (tSMARTseq) or TARGET-seq reveals very good correlations between methods.

2019-02-11 | GSE105451 | GEO

3'-TARGET-seq: a novel method for high-sensitivity single-cell mutational analysis and parallel high throughput RNA-sequencing [Figures 5 and 6, Figure S7]

Project description:3'-TARGET-seq: a novel method for high-sensitivity single-cell mutational analysis and parallel high throughput RNA-sequencing [Figures 5 and 6, Figure S7]

| PRJNA503903 | ENA

3'-TARGET-seq: a novel method for high-sensitivity single-cell mutational analysis and parallel high throughput RNA-sequencing [Figures 5 and 6, Figure S7]

Project description:We developed 3'-TARGET-seq, a single-cell genotyping and RNA-seq method, which allows accurate detection of multiple mutations within single-cells from genomic and coding DNA in parallel with high throughput 3'-biased whole transcriptome analysis, providing a powerful tool to link transcriptional and genetic tumor heterogeneity. Single cell whole transcriptome sequencing of 2798 Lineage-CD34+ HSPC (Hematopoietic Stem and Progenitor Cells) from patients with JAK2-V617F mutant myelofibrosis and normal controls using 3'-TARGET-seq reveals distinct molecular signatures associated with the presence of somatic mutations in single cells as well as distinct transcriptional profiles of WT cells from patient samples as compared with normal controls.

2019-02-11 | GSE122198 | GEO

TARGET-seq: novel method for single-cell mutational analysis and parallel RNA-sequencing

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-02-11 | GSE105454 | GEO

Massively parallel quantification of mutational impact on IAPP amyloid formation

Project description:Massively parallel quantification of mutational impact on IAPP amyloid formation

| PRJNA1184712 | ENA

A Novel RNA Sequencing Data Analysis Method for Cell Line Authentication

Project description:We have developed a novel analysis method that can interrogate the authenticity of biological samples used for generation of transcriptome profiles in public data repositories. The method uses RNA sequencing information to reveal mutations in expressed transcripts and subsequently confirms the identity of analysed cells by comparison with publicly available cell-specific mutational profiles. Cell lines constitute key model systems widely used within cancer research, but their identity needs to be confirmed in order to minimise the influence of cell contaminations and genetic drift on the analysis. Using both public and novel data, we demonstrate the use of RNA-sequencing data analysis for cell line authentication by examining the validity of COLO205, DLD1, HCT15, HCT116, HKE3, HT29 and RKO colorectal cancer cell lines. We successfully authenticate the studied cell lines and validate previous reports indicating that DLD1 and HCT15 are synonymous. We also show that the analysed HKE3 cells harbour an unexpected KRAS-G13D mutation and confirm that this cell line is a genuine KRAS dosage mutant, rather than a true isogenic derivative of HCT116 expressing only the wild type KRAS. This authentication method could be used to revisit the numerous cell line based RNA sequencing experiments available in public data repositories, analyse new experiments where whole genome sequencing is not available, as well as facilitate comparisons of data from different experiments, platforms and laboratories.

2017-02-14 | GSE81194 | GEO

A deep mutational scanning platform to characterize the fitness landscape of anti-CRISPR proteins

Project description:Deep mutational scanning is a powerful method for exploring the mutational fitness landscape of proteins. Its adaptation to anti-CRISPR proteins, which are natural CRISPR-Cas inhibitors and key players in the co-evolution of microbes and phages, facilitates their characterization and optimization. Here, we developed a robust anti-CRISPR deep mutational scanning pipeline in Escherichia coli that combines synthetic gene circuits based on CRISPR interference with flow cytometry coupled sequencing and mathematical modeling. Using this pipeline, we characterized comprehensive single point mutation libraries for AcrIIA4 and AcrIIA5, two potent inhibitors of CRISPR-Cas9. The resulting mutational fitness landscapes revealed considerable mutational tolerance for both Acrs, suggesting an intrinsic redundancy with respect to Cas9 inhibitory features, and – for AcrIIA5 – indicated mutations that boost Cas9 inhibition. Subsequent in vitro characterization suggested that the observed differences in inhibitory potency between mutant inhibitors were mostly due to changes in binding affinity rather than protein expression levels. Finally, to demonstrate that our pipeline can inform Acrs-based genome editing applications, we employed a selected subset of mutant inhibitors to increase CRISPR-Cas9 target specificity by modulating Cas9 activity. Taken together, our work establishes deep mutational scanning as a powerful method for anti-CRISPR protein characterization and optimization.

2024-03-01 | GSE254101 | GEO

Massively parallel quantification of mutational impact on IAPP amyloid formation

Project description:Amyloid fibrils formed by the islet amyloid polypeptide (IAPP) cause pancreatic beta-cell damage, resulting in reduced insulin secretion and Type 2 diabetes (T2D). Variations in the primary amino acid sequence of IAPP can influence its aggregation rate and animals expressing IAPP variants that do not form amyloids, do not develop T2D. Conversely, specific single amino -acid changes in IAPP are enough to accelerate its aggregation rate. Understanding how mutations impact IAPP aggregation can help gain mechanistic understanding into the process of pathogenic amyloid formation of this peptide and preventively identify mutations that may contribute to the risk of developing T2D. Here, we employ deep mutational scanning to measure the ability to nucleate amyloids for 1663 IAPP variants, including substitutions, insertions, truncations and deletions and identify variants that increase amyloid formation in all mutation classes. Our results point at a continuous stretch of residues (15-32) which likely is structured in IAPP amyloids and that matches the core of the early aggregated species formed by IAPP in vitro. Inside this region, mutations have a more drastic effect in the 21-27 NNFGAIL segment, suggesting tighter structural constraints for this stretch in IAPP amyloids. Finally, by comparing this mutational atlas to that of another amyloid, Amyloid beta (Aβ42), the peptide that aggregates in Alzheimer’s Disease, we find that the effects of mutations that slow down nucleation correlate between the two amyloids, but that when it comes to mutations that accelerate nucleation one single amyloid dataset cannot be used to predict mutational effects in the other.

2025-05-20 | GSE281555 | GEO

Mutational signatures

Project description:Mutational signatures

| PRJEB60585 | ENA